Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Orion Capital Management LLC

Orion Capital Management LLC trimmed its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 10,109 shares of the medical equipment provider’s stock after selling 450 shares during the quarter. Intuitive Surgical accounts for approximately 2.0% of Orion Capital Management LLC’s portfolio, making the stock its 14th biggest position. Orion Capital Management LLC’s holdings in Intuitive Surgical were worth $3,410,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Victory Capital Management Inc. boosted its position in shares of Intuitive Surgical by 6.8% in the 4th quarter. Victory Capital Management Inc. now owns 504,850 shares of the medical equipment provider’s stock valued at $170,316,000 after purchasing an additional 32,362 shares during the period. Savant Capital LLC boosted its stake in Intuitive Surgical by 45.7% in the 4th quarter. Savant Capital LLC now owns 4,811 shares of the medical equipment provider’s stock valued at $1,623,000 after buying an additional 1,509 shares in the last quarter. Certuity LLC boosted its stake in Intuitive Surgical by 12.9% in the 4th quarter. Certuity LLC now owns 2,199 shares of the medical equipment provider’s stock valued at $742,000 after buying an additional 252 shares in the last quarter. Penobscot Investment Management Company Inc. boosted its stake in Intuitive Surgical by 15.4% in the 4th quarter. Penobscot Investment Management Company Inc. now owns 2,355 shares of the medical equipment provider’s stock valued at $794,000 after buying an additional 315 shares in the last quarter. Finally, Kestra Private Wealth Services LLC boosted its stake in Intuitive Surgical by 9.9% in the 4th quarter. Kestra Private Wealth Services LLC now owns 4,140 shares of the medical equipment provider’s stock valued at $1,397,000 after buying an additional 373 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical Stock Up 2.1 %

Shares of ISRG stock traded up $7.76 during trading hours on Wednesday, reaching $378.38. The company’s stock had a trading volume of 507,452 shares, compared to its average volume of 1,630,907. The firm’s 50 day simple moving average is $385.96 and its 200-day simple moving average is $348.19. The company has a market capitalization of $134.21 billion, a price-to-earnings ratio of 66.90, a PEG ratio of 4.83 and a beta of 1.36. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.10. The firm had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business’s quarterly revenue was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.00 earnings per share. Sell-side analysts predict that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Insider Buying and Selling

In other news, SVP Mark Brosius sold 196 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the sale, the senior vice president now owns 1,842 shares of the company’s stock, valued at approximately $736,800. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, EVP Robert Desantis sold 20,296 shares of the company’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the sale, the executive vice president now directly owns 5,507 shares in the company, valued at approximately $2,168,656.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Mark Brosius sold 196 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the sale, the senior vice president now owns 1,842 shares in the company, valued at $736,800. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 226,967 shares of company stock worth $87,848,586. Corporate insiders own 0.90% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the company. Mizuho boosted their price target on Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research note on Thursday, January 25th. BTIG Research boosted their price target on Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research note on Friday, April 19th. Royal Bank of Canada boosted their price target on Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a research note on Wednesday, January 24th. Stifel Nicolaus boosted their price objective on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Finally, Barclays boosted their target price on Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a research report on Thursday, January 25th. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $396.17.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.